JP Morgan Healthcare Conference

Transcription

1 JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14, 2014

2 Forward-Looking Information During this meeting, we will make statements about the Company s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. 2

3 Our Strategic Foundation Best of Biotech Best of Pharma Helping more patients prevail in their fight against serious disease Leading BioPharma Company Innovation Selective Integration Continuous Improvement Agile, Entrepreneurial & Accountable Culture 3

4 Evolution of BioPharma Strategy Innovative Pharmaceuticals Specialty Care BioPharma

5 Diabetes Divestiture: Strategic Rationale Next step in evolution to a specialty care biopharma company Sharpen focus and resources on promising growth opportunities Improves and strengthens financial position Provides opportunity to simplify operating model Allows optimization of diabetes portfolio 5

6 Keys to Future Growth Invest for long-term growth balance short-term results Drive growth of key brands Execute new product launches Invest to deliver late stage pipeline Maintain culture of continuous improvement Pursue disciplined capital allocation 6

7 Improving the standard of care in stroke prevention Unique and differentiated profile Investing to maximize potential Encouraging trends in priority areas Potential near term label expansion 7

8 Hepatitis C: A Global Opportunity Europe Daclatasvir filed and granted expedited review US Potential filing in the first half of 2014 Japan Potentially the first all oral therapy All oral triple regimen in Phase III 8

9 Immuno-Oncology Development Portfolio Phase I Phase II Registrational Approved Indications Anti-LAG3 Cancer Lirilumab* (Anti-KIR) Cancer Urelumab (Anti-CD137) Cancer HCC Hematologic Mal. + Lirilumab Cancer (solid tumor) + Lirilumab Cancer (solid tumor) + Denenicokin Cancer (solid tumor) + Cancer (solid tumor) + Cancer (NSCLC) + Cancer (RCC) SPRYCEL + CML^ Elotuzumab* 2 nd line MM Velcade Combo Gastric Ovarian Adolescent melanoma + GBM^ Elotuzumab* 1 st line MM Revlimid Combo Elotuzumab* Relapsed/Refractory MM Revlimid Combo 2 nd /3 rd line RCC 2 nd line Sq NSCLC 2 nd line NSq NSCLC 3 rd line Sq NSCLC 1 st line Melanoma 2 nd /3 rd line Melanoma *Development Partnership Nivolumab: Ono Pharmaceuticals; Elotuzumab: AbbVie; Lirilumab: Innate Pharma + 1 st line Melanoma Metastatic Melanoma Dose Optimization Adjuvant Melanoma 1 st line Sq NSCLC Small Cell Lung Prostate (post hormonal therapy) Unresectable or Metastatic Melanoma Abbreviations: CML: Chronic Myelogenous Leukemia HCC: Hepatocellular Carcinoma Loc. Adv.: Locally Advanced Mal: Malignancies, Met: Metastatic MM: Multiple Myeloma NSq: Non-Squamous, Sq: Squamous NSCLC: Non Small Cell Lung Cancer RCC: Renal Cell Carcinoma ^Published on ClinicalTrials.gov, not yet recruiting 9

10 Capital Allocation: A Balanced Approach Continue to be in a strong financial position: Business development remains a top priority Dividend commitment 5 th consecutive annual increase Share repurchases possible 10

11 Business Development: Core to Our Strategy Licensing Acquisition Partnerships Strategically, Scientifically & Financially Aligned 11

12 Confident in Our Future Exciting long-term potential Innovative late-stage pipeline Continued evolution of specialty model Disciplined capital allocation Positioned for long-term success 12

13 JP Morgan Healthcare Conference Lamberto Andreotti Chief Executive Officer January 14,